What is Notable Labs?
Notable Labs is dedicated to revolutionizing cancer treatment by precisely identifying effective drug combinations for specific patient groups, particularly those with unmet needs. By focusing on predicting high success rates for targeted therapies, the company aims to improve patient outcomes and streamline the drug development process. This approach positions Notable Labs at the forefront of personalized oncology, leveraging data-driven insights to combat complex blood cancers.
How much funding has Notable Labs raised?
Notable Labs has raised a total of $57.4M across 6 funding rounds:
Angel/Seed
$6M
Other Financing Round
$50K
Series A
$10M
Series B
$40M
Debt
$350K
Debt
$1M
Angel/Seed (2015): $6M with participation from Accelerate Brain Cancer Cure, Eric Kwan, First Round Capital, Y Combinator, 11.2 Capital, UpHonest Capital, and Refactor Capital
Other Financing Round (2016): $50K led by Undisclosed
Series A (2017): $10M supported by Builders VC
Series B (2019): $40M featuring Lifeforce Capital Gp I and B Capital Group
Debt (2020): $350K backed by PPP
Debt (2021): $1M with participation from PPP
Key Investors in Notable Labs
B Capital Group
B Capital is a venture capital firm that focuses on empowering entrepreneurs by investing in early and late-stage companies within the Technology, Healthcare, and Climate sectors. With over $8 billion in assets under management and a portfolio comprising more than 190 companies, B Capital aims to support founders throughout the company-building lifecycle.
First Round Capital
Baseline Ventures is a venture capital firm that invests in innovative startups across various sectors. The company focuses on supporting entrepreneurs and helping them achieve significant results, with a notable track record of successful IPOs and acquisitions.
Y Combinator
Established in 2005 and located in Mountain View, California, Y Combinator provides seed funding for startup businesses and to gauge investors for businesses.
What's next for Notable Labs?
With its recent major strategic investment and substantial overall capital, Notable Labs is poised for accelerated expansion and further development of its predictive oncology platform. The company's trajectory suggests a focus on scaling its operations, forging new partnerships within the pharmaceutical and biotech sectors, and potentially advancing its therapeutic candidates through clinical trials. This infusion of capital will likely fuel innovation in its data analytics capabilities and broaden its reach to more patient populations.
See full Notable Labs company page
